Xenon Pharmaceuticals' (XENE) CEO Ian Mortimer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate UpdateGlobeNewsWire • 11/03/21
Earnings Preview: Xenon Pharmaceuticals (XENE) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21
Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/08/21
Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary EndpointBenzinga • 10/04/21
Tesla Sets Delivery Records, but This Nasdaq Stock Was the Big Premarket Winner MondayThe Motley Fool • 10/04/21
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal EpilepsyGlobeNewsWire • 10/04/21
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE' Clinical Trial of XEN1101GlobeNewsWire • 10/03/21